Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Assay Detects Bacterial Toxin Genes

By LabMedica International staff writers
Posted on 13 Dec 2010
A rapid molecular test specifically identifies the bacteria Clostridium difficile within 24 hours.

The assay is very sensitive and detects the large clostridial cytotoxins of C. More...
difficile, the toxin A gene (tcdA) in addition to the toxin B gene (tcdB) and has some advantages over other tests.

A study was conducted at University of Utah School of Medicine, (Salt Lake City, UT, USA; medicine.utah.edu) to compare the abilities of two different assays to recognize various C. difficile-strain types and toxin classes and to determine cross reactivity with other Clostridium species. The study involved 40 clinical isolates from 20 species of C. difficile and non–C. difficile samples from stool samples.

The two assay tested were the illumigene C. difficile assay (Meridian Biosciences, Cincinnati, OH, USA), which targets the highly conserved 5′ region of tcdA, using loop-mediated isothermal amplification (LAMP), and tcdB; and the GeneOhm C. difficile assay (BD Diagnostics, Franklin Lakes, NJ, USA). The two assays were 100% concordant in identifying the B+ strains of C. difficile. The illumigene assay was able to detect toxin A+B+ strains of toxinotypes 0 (16 strains), III (6 strains), V (6 strains), XII (1 strain), and IX/XXIII (1 strain). It also amplified AB+ strains of toxinotypes VIII (three strains) and X (one strain). As a negative control, neither assay was able to amplify 34 non–C difficile, other Clostridium species isolates, including three of the closely related Clostridium sordelii.

Brianne Couturier, PhD, from the University of Utah, preferred the illumigene assay and said, "The BD GeneOhm has the same license mechanism; however, you have to make up the master mix separately. If you do not make full runs, you are wasting reagent, whereas with the illumigene assay you do not waste reagents." The workflow is improved and technician time is saved. The results of the study were presented at the Annual Meeting of the Association for Molecular Pathology, November 17-20, 2010, held in San Jose, CA, USA.

Related Links:
University of Utah School of Medicine
Meridian Biosciences
BD Diagnostics


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.